

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ
<u>泉並木</u>	HCV 抗体が毎年陽性になります		NHK テキストきょうの健康	NH出版	東京	2022	106
<u>泉並木</u>	HCV 撲滅に向けた地域・院内における取組	泉並木	肝臓クリニカルアップデート	医学図書出版	東京	2022	93-100
<u>泉並木</u>	ウイルス肝炎治療の変遷と展望	茶山一彰	日本臨床ウイルス肝炎学 2023	日本臨床社	東京	2023	42-45
宮田 明典、河口 義邦、長谷川 潔	【肝疾患】転移性肝癌・肝細胞癌	中島 淳	最新ガイドラインに基づく消化器疾患診療指針 2023-24	総合医学社	日本	2023	283-293
鍛冶孝祐 <u>吉治仁志</u>	非代償性肝硬変に対する薬物治療(再生・抗ウイルス治療を除く)	竹原徹郎	最新主要文献とガイドラインでみる消化器内科学レビュー 2022-'23	総合医学社	東京	2022	208-212
<u>吉治仁志</u>	肝細胞癌に対する最新の薬物療法	吉治仁志	日本消化器病学会雑誌 119 巻5号	日本消化器病学会	東京	2022	389-402
<u>吉治仁志</u>	消化器医のためのアルコール臓器障害診療マニュアルー減酒療法のススメ	吉治仁志	消化器医のためのアルコール臓器障害診療マニュアルー減酒療法のススメ	南江堂	東京	2022	1-168

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Nakatsuka T, <u>Tateishi R</u> , Nakagomi R, Minami T, <u>Koike K.</u>	Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan.	J Hepatol	77(2)	569-571	2022
Fukumoto T, Minami T, Moriyama M, Yamada T, Wake T,	Improved prognosis of hepatitis C-related hepatocellular carcinoma	Hepatol Commun	6(9)	2496-2512	2022

Kinoshita MN, Fujiwara N, Nakagomi R, Nakatsuka T, Sato M, Enooku K, Nakagawa H, Fujishiro M, Shiina S, <u>Koike K</u> , <u>Tateishi R</u> .	in the era of direct-acting antivirals.				
Okushin K, <u>Tateishi R</u> , Takahashi A, Uchino K, Nakagomi R, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, Kanto T, Kubo S, Yoshiji H, Miyata H, Izumi N, Kudo M, <u>Koike K</u> .	Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL).	J Gastroenterol	57(8)	587-597	2022
Takayama T, Hasegawa K, Izumi N, Kudo M, Shimada M, Yamanaka N, Inomata M, Kaneko S, Nakayama H, Kawaguchi Y, Kashiwabara K, <u>Tateishi R</u> , Shiina S, <u>Koike K</u> , Matsuyama Y, Omata M, Makuuchi M, Kokudo N.	Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial).	Liver Cancer	11(3)	209-218	2022
Nakatsuka T, <u>Tateishi R</u> , Nakagomi R, Minami T, <u>Koike K</u> .	Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan.	J Hepatol	77(2)	569-571	2022
Shimakami T, Setoyama H, Oza N, Itakura J, Kaneko S, Korenaga M, Toyama T, Tanaka J, Kanto T*.	Development of performance indicators for hepatitis countermeasures as a tool for the assessment and promotion of liver cancer prevention in Japan.	J Gastroenterol	58	257-267	2023
Hussain MRA, Hiebert L, Sugiyama A, Ouoba S, Bunthen E, Ko K, Akita T, Kaneko S, Kanto T, Ward JW, Tanaka J.	Effect of COVID-19 on hepatitis B and C virus countermeasures: Hepatologist responses from nationwide survey in Japan.	Hepatol Res	52	899-907	2022
Tanaka J, Kurisu A, Ohara M, Ouoba S, Ohisa M, Sugiyama A, Wang ML, Hiebert	Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan: A simulation study.	Lancet Reg Health West Pac.	22	100428	2022

L, <u>Kanto T</u> , Akita T.					
<u>Kudo M</u> , Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Vogel A, Tovoli F, Ueshima K, Aikata H, López López C, Pracht M, Meng Z, Daniele B, Park JW, Palmer D, Tamai T, Saito K, Dutcus CE, Lencioni R	Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.	J Hepatol	78	133-141	2023
<u>Kudo M</u>	Prioritized requirements for first-line systemic therapy for hepatocellular carcinoma: Broad benefit with less toxicity.	Liver Cancer	12	1-6	2023
Abou-Alfa GK, Lau G, <u>Kudo M</u> , Chan SL, Kelly RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgue A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Gupta C, Makowsky M, Kurland JF, Negro A, Sangro B, fro the HIMALAYA Investigators	Plain language summary of results from the HIMALAYA study: tremelimumab and durvalumab for the treatment of participants with unresectable hepatocellular carcinoma.	Future Oncol	17		2023
Nishida N, <u>Kudo M</u>	Artificial intelligence models for the diagnosis and management of liver diseases.	Ultrasonography	42	10-19	2023
Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, <u>Kudo M</u> , Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Solda C, Piscaglia F,	Atezolizumab plus bevacizumab versus Lenvatinib for unresectable hepatocellular carcinoma: a large real life worldwide population.	Eur J Cancer	180	9-20	2023

<p>Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costazo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S, Cucchetti A</p>					
<p>Talbot T, D'Alessio A, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Dharmapuri S, Ang C, Saeed A, Hildebrand H, Muzaffar M, Fulgenzi CAM, Amara S, Naqash AR, Gampa A, Pillai A, Wang Y, Khan U, Lee PC, Huang YH, Bengsch B, Bettinger D, Abugabal YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, <u>Kudo M</u>, Weinmann A, Galle PR, Muhammed A, Cortellini A, Vogel A, Pinato DJ</p>	<p>Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an international observational study.</p>	<p>Liver Int</p>	<p>43</p>	<p>695-707</p>	<p>2023</p>

Thabut D [†] , <u>Kudo M</u> [†] ([†] Shared 1st authors)	Treatment of portal hypertension in patients with HCC at the era of Baveno VII.	J Hepatol	78	658-662	2023
Aramaki O, Takayama T, Matsuyama Y, Kubo S, Kokudo N, Kurosaki M, Murakami T, Shiina S, <u>Kudo M</u> , Sakamoto M, Nakashima O, Fukumoto T, Iijima H, Eguchi S, Soejima Y, Makuuchi M	Reevaluation of Makuuchi's criteria for resecting hepatocellular carcinoma: a Japanese nationwide survey.	Hepatol Res	53	127-134	2023
Wu YL, van Hyfte G, Özbek U, Reincke M, Gampa A, Mohamed Y, Nishida N, Wietharn B, Amara S, Lee PC, Scheiner B, Balcar L, Pinter M, Vogel A, Weinmann A, Saeed A, Pillai A, Rimassa L, Naqash AR, Muzaffar M, Huang YH, Kaseb AO, <u>Kudo M</u> , Pinato D, Ang C	Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.	Front Oncol	13	1128569	2023
Persano M, Rimini M, Tada T, Suda G, Shimose S, <u>Kudo M</u> , Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Pressiani T, Piscaglia F, Kumada T, Rimassa L, Scartozzi M, Cascinu S, Casadei-Gardini A	Identification of Atezolizumab plus Bevacizumab prognostic index via recursive partitioning analysis in HCC: the ABE index.	Anticancer Res	43	1599-1610	2023
Hasegawa K, Takemura N, Yamashita T, Watadani T, Kaibori M, Kubo S, Shimada M, Nagano H, Hatano E, Aikata H, Iijima H, Ueshima K, Ohkawa K, Genda T, Tsuchiya K, Torimura T, Ikeda M, Furuse J, Akahane M, Kobayashi S, Sakurai H, Takeda A, Murakami T,	Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC guidelines).	Hepatol Res	53	383-390	2023

Motosugi U, Matsuyama Y, <u>Kudo M</u> , Tateishi R					
Kato N, <u>Kudo M</u> , Tsuchiya K, Hagihara A, Numata K, Aikata H, Inaba Y, Kondo S, Motomura K, Okano N, Ikeda M, Morimoto M, Kuroda S, Kimura A	Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: final results of a multicenter phase 2 study.	Hepatol Res	53	409-416	2023
Hagiwara S, Nishida N, <u>Kudo M</u>	Advances in immunotherapy for hepatocellular carcinoma.	Cancers	15	2070 doi:10.3390/cancers15072070	2023.
Manabe T, Ogawa C, Kakuma K, Nakahara M, Oura K, Tadokoro T, Fujita K, Tani J, Shibatoge M, Morishita A, <u>Kudo M</u> , Masaki T	Usefulness of the measurement of psoas muscle volume for sarcopenia diagnosis in patients with liver disease.	Diagnostics	13	1245 doi:10.3390/diagnostics13071245	2023.
Rimini M, Persano M, Tada T, Suda G, Shimose S, <u>Kudo M</u> , Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Soldà C, Piscablia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui	Real world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: How does adherence to the IMbrave150 trial inclusion criteria impact prognosis?	Targeted Oncol	18	221-233	2023

A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Corte AD, Ratti F, De Cobelli F, Aldrighetti L, Scartozzi M, Casinu S, Casadei-Gardini A					
<u>Kudo M</u>	Newly developed modified ALBI grade shows better prognostic and predictive value for hepatocellular carcinoma	Liver Cancer	11	1-8	2022
<u>Kudo M</u> , Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Kubo S	Report of the 22nd nationwide follow-up survey of primary liver cancer in Japan (2012–2013).	Hepatol Res	52	5-66	2022
<u>Kudo M</u> , Ikeda M, Ueshima K, Sakamoto M, Shiina S, Tateishi R, Nouse K, Hasegawa K, Furuse J, Miyayama S, Murakami T, Yamashita T, Kokudo N	Response evaluation criteria in cancer of the liver (version 6) (RECICL 2021 revised version).	Hepatol Res	52	329-336	2022
<u>Kudo M</u>	Durvalumab plus tremelimumab: A novel combination Immunotherapy for unresectable hepatocellular carcinoma.	Liver Cancer	11	87-93	2022
<u>Kudo M</u>	New treatment paradigm with systemic therapy in Intermediate-stage hepatocellular carcinoma.	Int J Clin Oncol	27	1110-1119	2022
<u>Kudo M</u> , Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Yau T, Gurary EB, Siegel AB, Wang A,	Updated efficacy and safety of KEYNOTE-224: a phase 2 study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.	Eur J Cancer	167	1-12 doi:10.1016/j.ejca.2022.02.009	2022

Cheng AL, Zhu AX, on behalf of the KEYNOTE-224 Investigators					
<u>Kudo M</u>	Selection of systemic treatment regimen for unresectable hepatocellular carcinoma: Does etiology matter?	Liver Cancer	11	283-289	2022
<u>Kudo M, Ueshima K,</u> Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Moriguchi M, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Ogasawara S, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson P, Arai Y	Final results of TACTICS: A randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma.	Liver Cancer	11	354-367	2022
<u>Kudo M</u>	Combination immunotherapy with anti- PD-1/PD-L1 antibody plus anti-VEGF antibody may promote cytotoxic T lymphocyte infiltration in hepatocellular carcinoma, including in the non- inflamed subclass.	Liver Cancer	11	185-191	2022
<u>Kudo M</u>	Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.	Hepatobil Surg Nutr	11	592-596	2022
<u>Kudo M</u>	Implications of the TACTICS trial: Establishing the new concept of combination/sequential systemic therapy and TACE to achieve synergistic effects.	Liver Cancer	11	487-496	2022
<u>Kudo M, Montal R,</u> Finn R, Castet F, Ueshima K, Nishida N, Haber PK, Hu Y, Chiba Y, Schwartz M, Meyer T, Lencioni R, Llovet JM	Objective response predicts survival in advanced hepatocellular carcinoma treated with systemic therapies.	Clin Cancer Res	28	3443-3451	2022
Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, <u>Kudo M, Harding JJ,</u>	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a	Lancet Oncol	23	77-90	2022

Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B	randomised, multicentre, open-label, phase 3 trial.				
Aoki T, Nishida N, <u>Kudo M</u>	Current perspectives on the immunosuppressive niche and role of fibrosis in hepatocellular carcinoma and the development of anti-tumor immunity.	J Histochem Cytochem	70	53-81	2022
Aoki T, Nishida N, <u>Kudo M</u>	Clinical significance of the duality of Wnt/ β -catenin signaling in human hepatocellular carcinoma.	Cancers	14	444 doi:10.3390/cancers14020444	2022
Yamagishi S, Doman K, Mekada Y, Nishida N, <u>Kudo M</u>	Detection and tracking of liver tumors for ultrasound diagnostic support using deep learning.	Journal of Image and Graphics (JOIG)	10	50-55 doi:10.18178/joig.10.1.50-55	2022
Nishida N, Yamakawa M, Shiina T, Mekada Y, Nishida M, Sakamoto N, Nishimura T, Iijima H, Hirai T, Takahashi K, Sato M, Tateishi R, Ogawa M, Mori H, Kitano M, Toyoda H, Ogawa C, <u>Kudo M</u> , JSUM AI investigators	Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts.	J Gastroenterol	57	309-321	2022
Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel AB, Dubrovsky L, <u>Kudo M</u>	Randomized phase 3 LEAP-012 study: Transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment.	Cardiovasc Intervent Radiol (CVIR)	45	405-412	2022
Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, <u>Kudo M</u> , Breder V, Merle P, Kaseb A, Li D, Verret W, Ma N, Nicholas A,	Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.	J Hepatol	76	862-873	2022

Wang Y, Li L, Zhu AX, Finn RS					
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, <u>Kudo M</u>	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria -Multicenter analysis.	Hepatol Res	52	308-316	2022
Hagiwara S, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Aoki T, Morita M, Chishina H, Komeda Y, Yoshida A, Park AM, Sato M, Kawada A, Nakano H, Nakagawa H, <u>Kudo M</u>	Role of phlebotomy in the treatment of liver damage related to erythropoietic porphyria.	Sci Rep	12	6100	2022
Minami Y, Takaki H, Yamakado K, <u>Kudo M</u>	How compatible are immune checkpoint inhibitors and thermal ablation for liver metastases?	Cancers	14	2206 doi.org/10.3390	2022
Chan HLY, Vogel A, Berg T, de Toni E, <u>Kudo M</u> , Trojan J, Weinmann A, Eiblmaier A, Klein HG, Hegel JK, Sharma A, Madin K, Rolny V, Lisy MR, Piratvisuth T	Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis.	JGH Open		292-300 doi:10.1002/jgh3.12720	2022
Abou-Alfa G [†] , Lau G [†] , <u>Kudo M</u> [†] , Chan SL [†] , Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Tu DV,	Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.	New Engl J Med Evidence		DOI:10.1056/EVIDoa2100070	2022

De Toni E, Rimassa L, Breder V, Vasilyev A, Heurgue A, Tam V, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle P, Ali S, Marcovitz M, Makowsky M, Pharm D, He P, Kurland JF, Negro A, Sangro B (†Shared 1st authors)					
Chan SL, Schuler M, Kang YK, Yen CJ, Edeline J, Choo SP, Lin CC, Okusaka T, Weiss KH, Macarulla T, Cattan S, Blanc JF, Lee KH, Maur M, Pant S, <u>Kudo M</u> , Assenat E, Zhu AX, Yau T, Lim HY, Bruix J, Geier A, Guillen-Ponce C, Fasolo A, Finn RS, Fan J, Vogel A, Qin S, Riester M, Katsanou V, Chaudhari M, Kakizume T, Gu Y, Porta DG, Myers A, Myers A, Delord JP	A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or Biomarker-selected solid tumors.	J Exp Clin Cancer Res	41	189 https://doi.org/10.1186/s13046-022-02383-5	2022
Tanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M,	Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.	Hepatol Res	52	773-783	2022

Hiasa Y, <u>Kudo M</u> , Kumada T					
Marinelli B, Kim E, D'Alessio A, Cedillo M, Sinha I, Debnath N, Pathel RS, <u>Kudo M</u> , Nishida N, Saeed A, Hildebrand H, Kaseb A, Abugabal Y, Pillai A, Huang YH, Khan U, Muzaffar M, Naqash AR, Fischman A, Bishay V, Bettinger D, Sung M, Ang C, Schwartz M, Pinato DJ, Marron TU	Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study.	J Immunother Cancer	10	e004205 doi:10.1136/jitc-2021-004205	2022
Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee CJ, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Kaseb A, Huang YH, Ang C, <u>Kudo M</u> , Nishida N, Personeni N, Rimassa L, Pinato DJ	Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in hepatocellular carcinoma.	Hepatology Commun	6	1776-1785 doi.org/10.1002/hep4.1927	2022
Verset G, Borbath I, Karwal M, Verslype C, Van Vierberghe H, Kardosh A, Zagonel V, Stal P, Sarker D, Palmer D, Vogel A, Edeline J, Cattani S, <u>Kudo M</u> , Cheng AL, Ogasawara S, Daniele B, Chan S, Finn R, Knox J, Qin SK, Siegel A, Chisamore M, Hatogai K, Wang A, Zhu A	Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase 2 KEYNOTE-224 trial.	Clin Cancer Res	28	2547-2554	2022
Llovet JM, Singal AG, Villanueva A, Finn RS, <u>Kudo M</u> , Galle PR, Ikeda M, Callies S, McGrath LM, Wang C, Abada P, Widau RC,	Prognostic and predictive factors in patients with advanced HCC and elevated alpha-fetoprotein treated with ramucirumab in two randomized Phase III trials.	Clin Cancer Res	28	2297-2305	2022

Gonzalez-Gugel E, Zhu AX					
Kubo S, Shinkawa H, Asaoka Y, Ioka T, Igaki H, Izumi N, Itoi T, Unno M, Ohtuka M, Okusaka T, Kadoya M, <u>Kudo M</u> , Kumada T, Kokudo N, Sakamoto M, Sakurai H, Takayama T, Nakashima O, Nagata Y, Hatano E, Harada K, Murakami T, Yamamoto M	Liver Cancer Study Group of Japan clinical practice guidelines for intrahepatic cholangiocarcinoma.	Liver Cancer	11	290-314	2022
<u>Kudo M</u> [†] , <u>Ueshima K</u> [†] , Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Moriguchi M, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Ogasawara S, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson P, Arai Y ([†] Shared 1st authors)	Final results of TACTICS: A randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma.	Liver Cancer	11	354-367	2022
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohma H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Aoki T, Koizumi Y, Nakamura S, Joko K, Hiasa Y, <u>Kudo M</u>	Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis.	Eur J Gastroenter ol Hepatol	34	857-864	2022
Okushin K, Tateishi R, Takahashi A, Uchino K, Nakagomi	Launch of a nationwide registry for advanced liver diseases (REAL).	J Gastroenter ol	57	587-597	2022

R, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, Kanto T, Kubo S, Yoshiji H, Miyata H, Izumi N, <u>Kudo M</u> , Koike K: Current status of primary liver cancer and decompensated cirrhosis in Japan					
Okusaka T, <u>Kudo M</u> , Ikeda K, Ikeda M, Okita K, Sugawara M, Tamai T, Ren M, Saito K, Kumada H	Impact of bodyweight-based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma.	Hepatol Res	52	784-793	2022
Hagiwara S, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Aoki T, Morita M, Chishina H, Komeda Y, Yoshida A, Hayashi H, Nakagawa K, <u>Kudo M</u>	Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection.	Hepatol Res	52	754-761	2022
Hagiwara S, Yoshida T, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Aoki T, Morita M, Chishina H, Komeda Y, Yoshida A, Hayashi H, Nakagawa K, <u>Kudo M</u>	Progression from early to advanced stage of immune-related cholangitis.	Hepatol Res	52	888-892	2022
Ueshima K, Komemushi A, Aramaki T, Iwamoto H, Obi S, Sato Y, Tanaka T, Matsueda K, Moriguchi M, Saito H, Sone M, Yamagami T, Inaba Y, <u>Kudo M</u> , Arai Y	Clinical practice guidelines for hepatic arterial infusion chemotherapy with a port system proposed by the Japanese Society of Interventional Radiology and Japanese Society of implantable port assisted treatment.	Liver Cancer	11	407-425	2022
Fulgenzi CAM, Cheon J, D'Alessio A, Nishida N, Ang C, Marron TU, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang YH, Phen S, Naqash	Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.	Eur J Cancer	175	204-213	2022

AR, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, <u>Kudo M</u> , Rimassa L, Singal AG, Sharma R, Cortellini A, Gaillard VE, Chon HJ, Pinato DJ					
Vithayathil M, D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Personeni N, Pressiani T, Pinter M, Cortellini A, <u>Kudo M</u> , Rimassa L, Pinato DJ, Sharma R	Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.	Liver Int	42	2538-2547	2022
Rimini M, Rimassa L, Ueshima K, Burgio V, Shigeo S, Tada T, Suda G, Yoo C, Cheon J, Pinato DJ, Lonardi S, Scartozzi M, Iavarone M, Di Costanzo GG, Marra F, Soldà C, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Pressiani T, Nishida N, Iwamoto H, Sakamoto N, Ryoo BY, Chon HJ, Claudia F, Niizeki T, Sho T, Kang B, D'Alessio A, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M,	Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.	ESMO Open	7	100591	2022

Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimur T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Pedica F, De Cobelli F, Ratti F, Alrighetti L, <u>Kudo M</u> , Cascinu S, Casadei-Gardini A					
Hagiwara S, Komeda Y, Nishida N, Yoshida A, <u>Kudo M</u>	A case of HCC successfully treated with infliximab-steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy.	Cancer Rep	5	e1721 doi:10.1002/cnr2.1721	2022
Rimini M, Kang W, Burgio V, Persano M, Aoki T, Shimose S, Tada T, Kumada T, Sho T, Lai E, Celsa C, Campani C, Tonnini M, Tamburini E, Hiraoka A, Takaguchi K, Nishida N, Iwamoto H, Itobayashi E, Tsuji K, Sakamoto N, Ishikawa T, Toyoda H, <u>Kudo M</u> , Kawaguchi T, Hatanaka T, Nouso K, Suda G, Cabibbo G, Marra F, Della Corte A, Ratti F, Pedica F, De Cobelli F, Aldrighetti L, Scartozzi M, Cascinu S, Casadei-Gardini A	Validation of the easy-to-use Lenvatinib prognostic (LEP) index to predict prognosis in advanced hepatocellular carcinoma patients treated with Lenvatinib.	Hepatol Res	52	1050-1059	2022
Kim SK, Fujii T, Kim SR, Lim YS,	Hepatitis B virus treatment and hepatocellular	Liver Cancer	11	497-510	2022

Hagiwara S, <u>Kudo M</u>	carcinoma - controversies and approaches to consensus.				
Casadei-Gardini A, Rimini M, <u>Kudo M</u> , Shimose S, Tada T, Suda G, Goh MJ, Jefremow A, Scartozzi M, Cabibbo G, Campani C, Tamburini E, Tovoli F, Ueshima K, Aoki T, Iwamoto H, Torimura T, Kumada T, Hiraoka A, Atsukawa M, Itobayashi E, Toyoda H, Sakamoto N, Sho T, Kang W, Siebler J, Neurath MF, Burgio V, Cascinu S	REal life study of LEnVAtiNib therapy for HepAtocellular carcinoma: RELEVANT study.	Liver Cancer	11	527-539	2022
Li D, Toh HC, Merle P, Tsuchiya K, Harnandez S, Verret W, Nicholas A, <u>Kudo M</u>	Atezolizumab plus bevacizumab versus sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in the IMbrave150 randomized clinical trial.	Liver Cancer	11	558-571	2022
Wu YL, Fulgenzi CAM, D'Alessio A, Cheon J, Nishida N, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang YH, Phen S, Naqash AR, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, <u>Kudo M</u> , Rimassa L, Singal AG, Sharma R, Cortellini A, Gaillard VE, Chon HJ, Pinato D, Ang C	Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.	Cancers	14	5834 doi:10.3390/ /cancers142 35834	2022
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E,	Clinical predictor of urinary protein as adverse event associated with atezolizumab plus bevacizumab treatment for unresectable hepatocellular	Oncology	100	645-654	2022

Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Ohama H, Tada F, Nouse K, Morishita A, Tsutsi A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, <u>Kudo M</u>	carcinoma.				
Shinkawa H, Kubo S, et al.	Impact of laparoscopic parenchyma-sparing resection of lesions in the right posterosuperior liver segments on surgical outcomes: a multicenter study based on propensity score analysis	Surgery	171 (5)	1311-1319	2022
Morise Z, Kubo S, et al.	An international retrospective observational study of liver functional deterioration after repeat liver resection for patients with hepatocellular carcinoma	Cancers (Basel)	14 (11)	2598	2022
Okushin K,	Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL)	Journal of Gastroenterology	57 (8)	587-597	2022
Uchida-Kobayashi S, Kubo S, et al.	Efficacy of rechallenge transcatheter arterial chemoembolization after lenvatinib treatment for advanced hepatocellular carcinoma	JGH Open	6 (11)	754-762	2022
Kinoshita M, Kubo S, et al.	Increasing incidence and severity of post-hepatectomy adhesion around the liver may be influenced by the hepatectomy-related operative procedures	Asian Journal of Surgery	46 (1)	228-235	2023
Kubo S, et al.	Microsatellite instability in patients with hepatobiliary-pancreatic	International Journal of Clinical	27 (8)	1340-1347	2022

	malignancies in clinical practice (KHBO 1903)	Oncology			
Shirai D, Kubo S, et al.	Laparoscopic liver resection reduces postoperative infection in patients with hepatocellular carcinoma: a propensity score-based analysis	Surgical Endoscopy	36 (12)	9194-9203	2022
Tanaka S, Kubo S, et al.	Surgical outcomes for hepatocellular carcinoma in patients with Child–Pugh class B: A retrospective multicenter study	Journal of Gastrointestinal Surgery	27 (2)	283-295	2023
Tanaka S, Kubo S, et al.	Positioning of minimally invasive liver surgery for hepatocellular carcinoma: From laparoscopic to robot-assisted liver resection	Cancers (Basel)	15 (2)	488	2023
Aramaki O, Kubo S, et al.	Reevaluation of Makuuchi's criteria for resecting hepatocellular carcinoma: A Japanese nationwide survey	Hepatology Research	53 (2)	127-134	2023
Nomi T, Kubo S, et al.	Short- and long-term outcomes of laparoscopic versus open repeat liver resection for hepatocellular carcinoma: A multicenter study	Journal of Hepatology and Pancreatic Sciences	30 (3)	283-292	2023
Ando Y, Takahashi A, Fujii M, Hasegawa H, Kimura T, Yamamoto H, Tajima T, Nishiguchi Y, Kakeji Y, Miyata H, Kitagawa Y,	Survey Regarding Gastrointestinal Stoma Construction and Closure in Japan	Ann Gastroenterol Surg	6(2)	212-226.	2022
Hoshino N, Endo H, Hida K, Kumamaru H, Hasegawa H, Ishigame T, Kitagawa Y, Kakeji Y, Miyata H, Sakai Y,	Laparoscopic Surgery for Acute Diffuse Peritonitis Due to Gastrointestinal Perforation: A Nationwide Epidemiologic Study Using the National Clinical Database	Ann Gastroenterol Surg	6(3)	430-444.	2022
Kaibori M, Ichihara N, Miyata H, Kakeji Y, Nanashima A, Kitagawa Y, Yamaue H, Yamamoto M, Endo I,	Surgical outcomes of laparoscopic versus open repeat liver resection for liver cancers: A report from a nationwide surgical database in Japan	J Hepatology and Pancreatic Sci	29(8)	833-842.	2022
Kikuchi H, Endo H, Yamamoto H, Ozawa S, Miyata H, Kakeji	Impact of Reconstruction Route on Postoperative Morbidity After	Ann Gastroenterol Surg	6(1)	46-53.	2022

Y, Matsubara H, Doki Y, Kitagawa Y, Takeuchi H,	Esophagectomy: Analysis of Esophagectomies in the Japanese National Clinical Database				
Kofunato Y, Takahashi A, Gotoh M, Kakeji Y, Seto Y, Konno H, Kumamaru H, <u>Miyata H</u> , Marubashi S,	Geriatric Risk Prediction Models for Major Gastroenterological Surgery Using the National Clinical Database in Japan: A Multicenter Prospective Cohort Study	Ann Surg	275(6)	1112-1120.	2022
Kudo M, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, <u>Miyata H</u> , Kubo S,	Report of the 22nd nationwide follow-up Survey of Primary Liver Cancer in Japan (2012-2013)	Hepatol Res	52(1)	5-66.	2022
Kumamaru H, Kakeji Y, Fushimi K, Ishikawa K, B, Yamamoto H, Hashimoto H, Ono M, Iwanaka T, Marubashi S, Gotoh M, Seto Y, Kitagawa Y, <u>Miyata H</u> ,	Cost of postoperative complications of lower anterior resection for rectal cancer: a nationwide registry study of 15,187 patients	Surg Today	52(12)	1766-1774.	2022
Maeda H, Endo H, Ichihara N, <u>Miyata H</u> , Hasegawa H, Kamiya K, Kakeji Y, Yoshida K, Seto Y, Yamaue H, Yamamoto M, Kitagawa Y, Uemura S, Hanazaki K,	Correlation between surgical mortality for perforated peritonitis and days of the week for operations: A retrospective study using the Japanese National Clinical Database	Am J Surg	224(1 Pt B)	546-551.	2022
Mori T, Endo H, Misawa T, Yamaguchi S, Sakamoto Y, Inomata M, Sakai Y, Kakeji Y, <u>Miyata H</u> , Kitagawa Y, Watanabe M,	Involvement of a skill-qualified surgeon favorably influences outcomes of laparoscopic cholecystectomy performed for acute cholecystitis	Surg Endosc	36(8)	5956-5963.	2022
Nakajima Y, Tachimori H, Miyawaki Y, Fujiwara N, Kawada K, Sato H, <u>Miyata H</u> , Sakuramoto S, Shimada H, Watanabe M, Kakeji Y, Doki Y, Kitagawa Y,	A survey of the clinical outcomes of cervical esophageal carcinoma surgery focusing on the presence or absence of laryngectomy using the National Clinical Database in Japan	Esophagus	19(4)	569-575.	2022
Nakata K, Yamamoto H, <u>Miyata H</u> , Kakeji	Comparison of outcomes between laparoscopic and	Asian J Endosc Surg	15(1)	15-21.	2022

Y, Kitagawa Y, Nakamura M,	open pancreaticoduodenectomy without radical lymphadenectomy: Results of coarsened exact matching analysis using national database systems				
Nishigori T, Ichihara N, Obama K, Uyama I, <u>Miyata H</u> , Inomata M, Kakeji Y, Kitagawa Y, Sakai Y,	Prevalence and safety of robotic surgery for gastrointestinal malignant tumors in Japan	Ann Gastroenter ol Surg	6(6)	746-752.	2022
Okamura A, Yamamoto H, Watanabe M, <u>Miyata H</u> , Kanaji S, Kamiya K, Kakeji Y, Doki Y, Kitagawa Y,	Association Between Preoperative HbA1c Levels and Complications after Esophagectomy: Analysis of 15,801 Esophagectomies From the National Clinical Database in Japan	Ann Surg	276(5)	e393- e399.	2022
Okoshi K, Endo H, Nomura S, Kono E, Fujita Y, Yasufuku I, Hida K, Yamamoto H, <u>Miyata H</u> , Yoshida K, Kakeji Y, Kitagawa Y,	Comparison of short term surgical outcomes of male and female gastrointestinal surgeons in Japan: retrospective cohort study	Bmj	378	e070568.	2022
Okushin K, Tateishi R, Takahashi A, Uchino K, Nakagomi R, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, Kanto T, Kubo S, Yoshiji H, <u>Miyata H</u> , Izumi N, Kudo M, Koike K,	Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL)	J Gastroenter ol	57(8)	587-597.	2022
Suda K, Yamamoto H, Nishigori T, Obama K, Yoda Y, Hikage M, Shibasaki S, Tanaka T, Kakeji Y, Inomata M, Kitagawa Y, <u>Miyata H</u> , Terashima M, Noshiro H, Uyama I,	Safe implementation of robotic gastrectomy for gastric cancer under the requirements for universal health insurance coverage: a retrospective cohort study using a nationwide registry database in Japan	Gastric Cancer	25(2)	438-449.	2022
Uemura S, Endo H, Ichihara N, <u>Miyata H</u> , Maeda H, Hasegawa H, Kamiya K, Kakeji Y, Yoshida K, Yasuyuki S, Yamaue H, Yamamoto M, Kitagawa Y, Hanazaki K,	Day of surgery and mortality after pancreatoduodenectomy: A retrospective analysis of 29 270 surgical cases of pancreatic head cancer from Japan	J Hepatobiliar y Pancreat Sci	29(7)	778-784.	2022

Watanabe M, Toh Y, Ishihara R, Kono K, Matsubara H, Murakami K, Muro K, Numasaki H, Oyama T, Ozawa S, Saeki H, Tanaka K, Tsushima T, Ueno M, Uno T, Yoshio T, Usune S, Takahashi A, <u>Miyata H</u> ,	Comprehensive registry of esophageal cancer in Japan, 2014	Esophagus	19(1)	1-26.	2022
Hasegawa K, Takemura N, Yamashita T, Watadani T, Kaibori M, Kubo S, Shimada M, Nagano H, Hatano E, Aikata H, Iijima H, Ueshima K, Ohkawa K, Genda T, Tsuchiya K, Torimura T, Ikeda M, Furuse J, Akahane M, Kobayashi S, Sakurai H, Takeda A, Murakami T, Motosugi U, Matsuyama Y, Kudo M, <u>Tateishi R</u> , committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma TJ.	Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines).	Hepatol Res	53(5)	383-390	2023
Kudo M, Ikeda M, Ueshima K, Sakamoto M, Shiina S, <u>Tateishi R</u> , Nouse K, Hasegawa K, Furuse J, Miyayama S, Murakami T, Yamashita T, Kokudo N.	Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version).	Hepatol Res	52(4)	329-336	2022
Ichida A, Akamatsu N, Nagata R, Mihara Y, Kawaguchi Y, Bae SK, Ishizawa T, Kaneko J, Arita J, Hasegawa K.	Efficacy and Safety of Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Report of Two Cases.	Anticancer Res	42(2)	1161-1167	2022
Imamura H, Hasegawa K, Soejima Y, Saiura A.	Regarding "Postresection Period-Specific Hazard of Recurrence as a Framework for Surveillance Strategy in	Liver Cancer	11(5)	483-486	2022

	Patients with Hepatocellular Carcinoma: A Multicenter Outcome Study".				
Arita J, Ichida A, Nagata R, Mihara Y, Kawaguchi Y, Ishizawa T, Akamatsu N, Kaneko J, Hasegawa K.	Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.	J Hepatobiliary Pancreat Sci	29(7)	732-740	2022
Kokudo T, Ishizawa T, Nagata R, Ichida A, Mihara Y, Kawaguchi Y, Akamatsu N, Kaneko J, Arita J, Kokudo N, Hasegawa K.	Optimal tumor numbers in surgical candidates for multiple hepatocellular carcinomas.	Surgery	172(4)	1174-1178	2022
西岡 裕次郎, 長谷川 潔	【肝細胞癌診療 up-to-date】肝細胞癌に対する外科治療の現在 肝切除・肝移植	日本消化器病学会雑誌	120 巻 1 号	27-34	2023
伊藤 橋司, 市田 晃彦, 河口 義邦, 金子 順一, 赤松 延久, 有田 淳一, 長谷川 潔	【外科医が知っておくべき! 免疫チェックポイント阻害薬】肝細胞癌に対する免疫チェックポイント阻害薬 適応と有害事象, 進行中の臨床試験	臨床外科	78 巻 1 号	50-54	2023
西岡 裕次郎, 長谷川 潔	【術前画像の読み解きガイド-的確な術式選択と解剖把握のために】肝臓 肝癌 術前評価および蛍光ナビゲーション手術 術式選択のポイント	臨床外科	77 巻 11 号	184-189	2022
河口義邦、長谷川潔	【原発性肝癌診療ガイドラインを読み解く】肝癌診療ガイドライン第5版 肝癌診療ガイドライン第5版改訂のポイント	外科	84 巻 9 号	915-918	2022
市田 晃彦, 有田 淳一, 石沢 武彰, 赤松 延久, 金子 順一, 長谷川 潔	【肝胆膵癌における conversion therapy】肝細胞癌における conversion therapy レンバチニブによる conversion surgery	肝胆膵	84 巻 5 号	601-606	2022
田中 薫(ロコモディカル江口病院), 藤川 ありさ, 平川 美智子, 原 なぎさ, 福田 貴博, 江口 有一郎, 江口 尚久, 高橋 宏和	アルコール性肝障害に対する断酒・減酒についての継続的、段階的な多職種支援 単一医療機関での取り組み	日本病態栄養学会誌 (1345-8167)	26 巻 Suppl.	S-76	2023
原 なぎさ(佐賀大学)	拠点病院肝疾患センタ	日本病態栄	26 巻	S-37	2023

医学部附属病院 肝疾患センター), 川添 夕佳, 井上 香, 市丸 葉子, 平田 千聡, 吉田 紗也, 山口 詩織, 溝上 泰仁, 吉村 知加子, 田中 薫, 平川 美智子, 江口 有一郎, 高橋 宏和	一と門前薬局による NAFLD 撲滅を目指した取り組み	養学会誌 (1345-8167)	Suppl.		
Hanai T, Kawaratani H, Yoshiji H et al.	Cell-free and concentrated ascites reinfusion therapy versus large-volume paracentesis for the treatment of cirrhotic patients with refractory ascites: A multicenter prospective observational study	Hepatology Res	53	238-246	2023
Kawaratani H, Yoshiji H Koike K et al.	The Usefulness of the Athens Insomnia Scale for Evaluating Sleep Disturbance in Patients with Chronic Liver Disease Comparing with Pittsburgh Sleep Quality Index and Epworth Sleepiness Scale	Medicina (Kaunas)	58	741	2022
Hiraoka A, Yoshiji H et al.	Clinical features of patients with chronic liver disease in Japan related to alcohol use: Nationwide examination using alcohol use disorders identification test	Hepatology Res	53	43-50	2023
Nakayama T, Ito K, Inagaki F, Kobayashi M, Tanabe A, Mihara F, Takemura N, <u>Kokudo N</u> .	Repeat hepatectomy for massive liver metastases from pheochromocytoma: a case report.	Clin J Gastroenterol.		Epub ahead of print. doi:10.1007/s12328-023-01784-z. PMID:36943552.	2023
Yin KL, Li M, Song PP, Duan YX, Ye WT, Tang W, <u>Kokudo N</u> , Gao Q, Liao R.	Unraveling the Emerging Niche Role of Hepatic Stellate Cell-derived Exosomes in Liver Diseases.	J Clin Transl Hepatol.	11(2)	441-451	2023
Ichida A, Kokudo T, Shimada S, Hatano E, Kubo S, Kato Y, Ishikawa Y, Mori A, Baba H, Matsuyama Y, Endo I, Yamaue H, Yamamoto M, <u>Kokudo N</u> , Hasegawa	Liver resection for Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava or Right Atrium: A Large-scale Multicenter Survey Conducted in Japan.	Ann Surg.		Epub ahead of print. doi:10.1097/SLA.00000000000005789. PMID:6591790.	2023

K.					
Ito D, Kawaguchi Y, Inagaki Y, Ito K, Mihara Y, Kaneko J, Tanaka M, Fukayama M, <u>Kokudo N</u> , Hasegawa K.	Assessment of liver function-related mRNA expression and fluorescence imaging in outflow-obstructed regions in rats.	Surg Today.	53(4)	513-521.	2023
Makino Y, Hikita H, Kato S, Sugiyama M, Shigekawa M, Sakamoto T, Sasaki Y, Murai K, Sakane S, Kodama T, Sakamori R, Kobayashi S, Eguchi H, Takemura N, <u>Kokudo N</u> , Yokoi H, Mukoyama M, Tatsumi T, Takehara T.	STAT3 is Activated by CTGF-mediated Tumorstroma Cross Talk to Promote HCC Progression.	Cell Mol Gastroenterol Hepatol.	15(1)	99-119.	2023
Aramaki O, Takayama T, Matsuyama Y, Kubo S, <u>Kokudo N</u> , Kurosaki M, Murakami T, Shiina S, Kudo M, Sakamoto M, Nakashima O, Fukumoto T, Iijima H, Eguchi S, Soejima Y, Makuuchi M.	Reevaluation of Makuuchi's criteria for resecting hepatocellular carcinoma: A Japanese nationwide survey.	Hepatol Res.	53(2)	127-134.	2023
Kokudo T, <u>Kokudo N</u> , Hasegawa K.	Oncological benefit of anatomic resection for patients with hepatocellular carcinoma.	Surg Today.		Epub ahead of print. doi:10.1007/s00595-022-02616-2. PMID:36478034.	2022
Ishizawa T, McCulloch P, Stassen L, van den Bos J, Regimbeau JM, Dembinski J, Schneider-Koriath S, Boni L, Aoki T, Nishino H, Hasegawa K, Sekine Y, Chen-Yoshikawa T, Yeung T, Berber E, Kahramangil B, Bouvet M, Diana M, <u>Kokudo N</u> , Dip F, White K, Rosenthal RJ.	Assessing the development status of intraoperative fluorescence imaging for anatomy visualisation, using the IDEAL framework.	BMJ Surg Interv Health Technol.	4(1):	e000156.	2022
Sugita A, Inagaki FF,	Liver resection in a patient	Surg Case	8(1)	200.	2022

Takemura N, Nakamura M, Ito K, Mihara F, Yamamoto K, Morioka S, <u>Kokudo N</u> .	with persistent positive PCR test for coronavirus disease 2019 (COVID-19): a case report.	Rep.			
Norimatsu Y, Ito K, Takemura N, Inagaki F, Mihara F, <u>Kokudo N</u> .	Estimation of Physiologic Ability and Surgical Stress (E-PASS) Predicts Postoperative Major Complications After Hepato-Pancreato Biliary Surgery in the Elderly.	World J Surg.	46(11)	2788-2796.	2022
Ecker BL, Lee J, Saadat LV, Aparicio T, Buisman FE, Balachandran VP, Drebin JA, Hasegawa K, Jarnagin WR, Kemeny NE, Kingham TP, Groot Koerkamp B, <u>Kokudo N</u> , Matsuyama Y, Portier G, Saltz LB, Soares KC, Wei AC, Gonen M, D'Angelica MI.	Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis.	Lancet Oncol.	23(10)	1332-1342.	2022
Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Moriguchi M, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Ogasawara S, Yoshimura K, Okusaka T, Furuse J, <u>Kokudo N</u> , Okita K, Johnson PJ, Arai Y.	Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.	Liver Cancer.	11(4)	354-367.	2022
Görgec B, Cacciaguerra AB, Pawlik TM, Aldrighetti LA, Alseidi AA, Cillo U, <u>Kokudo N</u> , Geller DA, Wakabayashi G, Asbun HJ, Besselink MG, Cherqui D, Cheung TT, Clavien PA, Conrad C, D'Hondt M, Dagher I, Dervenis C, Devar J, Dixon E, Edwin B, Efanov M, Ettore	An International Expert Delphi Consensus on Defining Textbook Outcome in Liver Surgery (TOLS).	Ann Surg.	277(5)	821–8.	2022

GM, Ferrero A, Fondevilla C, Fuks D, Giuliante F, Han HS, Honda G, Inventarza O, Kooby DA, Lodge P, Lopez-Ben S, Machado MA, Marques HP, O'Rourke N, Pekolj J, Pinna AD, Portolani N, Primrose J, Rotellar F, Ruzzenente A, Schadde E, Siriwardena AK, Smadi S, Soubrane O, Tanabe KK, The CSC, Torzilli G, Van Gulik TM, Vivarelli M, Wigmore SJ, Abu Hilal M.					
Kokudo T, Ishizawa T, Nagata R, Ichida A, Mihara Y, Kawaguchi Y, Akamatsu N, Kaneko J, Arita J, <u>Kokudo N</u> , Hasegawa K.	Optimal tumor numbers in surgical candidates for multiple hepatocellular carcinomas.	Surgery.	172(4)	1174-1178.	2022
Akamatsu N, Hasegawa K, Nojiri K, Muto K, Shimizu J, Soeda E, Kawagishi N, Marubashi S, Mizuta K, Kaido T, Taketomi A, Ohdan H, Uemoto S, <u>Kokudo N</u> .	Long- term quality of life of living liver donors: A Japanese nationwide survey.	Liver Transpl.	28(11)	1800-1803.	2022
Otsubo T, Kobayashi S, Sano K, Misawa T, Katagiri S, Nakayama H, Suzuki S, Watanabe M, Ariizumi S, Unno M, Tanabe M, Nagano H, <u>Kokudo N</u> , Hirano S, Nakamura M, Shirabe K, Suzuki Y, Yoshida M, Takada Y, Nakagohri T, Horiguchi A, Ohdan H, Eguchi S, Ohtsuka M, Sho M, Rikiyama T, Hatano E, Taketomi A, Fujii T, Yamaue H, Miyazaki M,	A nationwide certification system to increase the safety of highly advanced hepatobiliary-pancreatic surgery.	J Hepatobiliary Pancreat Sci.	30(1)	60-71.	2023

Yamamoto M, Takada T, Endo I.					
Komoto I, <u>Kokudo N</u> , Aoki T, Morizane C, Ito T, Hashimoto T, Kimura W, Inoue N, Hasegawa K, Kondo S, Ueno H, Igarashi H, Oono T, Makuuchi M, Takamoto T, Hirai I, Takeshita A, Imamura M.	Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors.	Jpn J Clin Oncol.	52(7)	716-724.	2022
Isayama H, Tazuma S, <u>Kokudo N</u> , Tanaka A, Tsuyuguchi T, Nakazawa T, Notohara K, Mizuno S, Akamatsu N, Serikawa M, Naitoh I, Hirooka Y, Wakai T, Itoi T, Ebata T, Okaniwa S, Kamisawa T, Kawashima H, Kanno A, Kubota K, Tabata M, Unno M, Takikawa H; PSC guideline committee Members: Ministry of Health, Labour and Welfare (Japan) Research Project, The Intractable Hepatobiliary Disease Study Group.	Correction to: Clinical guidelines for primary sclerosing cholangitis 2017.	J Gastroenterol.	57(6)	453-454.	2022
Takemura N, Saiura A, Ito H, Ito K, Inagaki F, Mihara F, Yagi S, Enomoto N, Nohara K, Inoue Y, Takahashi Y, Yamada K, <u>Kokudo N</u> .	Proposal of new treatment algorithm for gastric cancer liver metastases: Up-front surgery or conversion surgery?	Glob Health Med.	4(1)	57-60.	2022
Watanabe G, Mise Y, Oba M, Saiura A, Inoue Y, Takahashi Y, Kishi Y, Suyama K, Takayama T, Noie T, Nishioka Y, Akamatsu N, Arita J, <u>Kokudo N</u> , Hasegawa K.	A multicenter phase II trial evaluating the efficacy of bevacizumab plus mFOLFOX6 for R0 surgical resection in advanced colorectal liver metastases harboring mutant-type KRAS: NEXTO-mt trial.	HPB (Oxford).	24(8)	1245-1251.	2022